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ABSTRACT
Objective Eosinophil predominant inflammation
characterises histological features of eosinophilic
oesophagitis (EoE). Endoscopy with biopsy is currently
the only method to assess oesophageal mucosal
inflammation in EoE. We hypothesised that
measurements of luminal eosinophil-derived proteins
would correlate with oesophageal mucosal inflammation
in children with EoE.
Design The Enterotest diagnostic device was used to
develop an oesophageal string test (EST) as a minimally
invasive clinical device. EST samples and oesophageal
mucosal biopsies were obtained from children
undergoing upper endoscopy for clinically defined
indications. Eosinophil-derived proteins including
eosinophil secondary granule proteins (major basic
protein-1, eosinophil-derived neurotoxin, eosinophil
cationic protein, eosinophil peroxidase) and Charcot–
Leyden crystal protein/galectin-10 were measured by
ELISA in luminal effluents eluted from ESTs and extracts
of mucosal biopsies.
Results ESTs were performed in 41 children with active
EoE (n=14), EoE in remission (n=8), gastro-oesophageal
reflux disease (n=4) and controls with normal
oesophagus (n=15). EST measurement of eosinophil-
derived protein biomarkers significantly distinguished
between children with active EoE, treated EoE in
remission, gastro-oesophageal reflux disease and normal
oesophagus. Levels of luminal eosinophil-derived
proteins in EST samples significantly correlated with peak
and mean oesophageal eosinophils/high power field
(HPF), eosinophil peroxidase indices and levels of the
same eosinophil-derived proteins in extracts of
oesophageal biopsies.
Conclusions The presence of eosinophil-derived
proteins in luminal secretions is reflective of mucosal
inflammation in children with EoE. The EST is a novel,
minimally invasive device for measuring oesophageal
eosinophilic inflammation in children with EoE.
BACKGROUND
Eosinophilic oesophagitis (EoE) is a chronic
oesophageal disease characterised by a constellation
of symptoms and eosinophil predominant
inflammation of the oesophageal epithelium.1 2
A significant problem besetting the understanding
of pathogenic mechanisms and the care of patients
with EoE is the identification and capture of bio-
markers of oesophageal inflammation. Except for
enumeration of eosinophils in oesophageal
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Significance of this study
What is already known on this subject?
▸ Eosinophilic oesophagitis (EoE) is a chronic
inflammatory disease characterised by
symptoms of oesophageal dysfunction and
oesophageal mucosal eosinophilia.
▸ Mucosal biopsy is required to make the
diagnosis and, in some cases, monitor disease
activity.
▸ Serum and stool biomarkers have provided
mixed results regarding disease activity in EoE.
What are the new findings?
▸ Oesophageal mucosal biopsy samples obtained
from patients with active eosinophilic
oesophagitis (EoE) contain increased quantities
of eosinophil granule proteins.
▸ Quantities of eosinophil granule proteins in
oesophageal luminal samples obtained with
the oesophageal string test correlate with
eosinophil counts and granule protein levels in
oesophageal tissues.
▸ Intraluminal sampling of the oesophageal
secretions can monitor histological
inflammation in EoE.
How might it impact on clinical practice in
the foreseeable future?
▸ The oesophageal string test might provide a
valuable device to measure inflammation in
patients with oesophagitis. The oesophageal
string test may offer significant value in
monitoring the impact of therapeutic
interventions on oesophageal inflammation in
patients with eosinophilic oesophagitis.
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biopsies, no validated measurements of oesophageal inflamma-
tion or disease activity have been identified. Previous studies
suggest that measurements of eosinophils as well as extracellular
eosinophil secondary granule protein (ESGP) deposition in the
oesophageal mucosa may serve as valuable measures of disease
activity in EoE.3–6
The ESGPs include four cationic proteins present in the eosi-
nophil’s large specific (secondary) granule known as major basic
protein-1 (MBP1), eosinophil peroxidase (EPX), eosinophil-
derived neurotoxin (EDN) and eosinophil cationic protein
(ECP). A fifth protein, the Charcot–Leyden crystal protein/
galectin-10 (CLC/Gal-10),7 is primarily a cytosolic protein, but
is also present in the eosinophil’s primary (coreless) granule.8
Each granule-associated protein carries different biochemical
and functional properties relevant to proposed pathogenetic
mechanisms for oesophageal dysfunction and remodelling in
EoE.9–12 Thus, measurement of eosinophil-derived proteins,
including ESGPs and CLC/Gal-10, within the oesophageal
mucosal microenvironment could provide both clinically rele-
vant information regarding EoE disease activity and novel
pathophysiological mechanisms.
To date, the only methodology to assess mucosal inflamma-
tion in patients with EoE is endoscopy and mucosal biopsy.
Correlation of symptoms with eosinophilic inflammation is vari-
able and peripheral measurements of eosinophil-associated bio-
markers from serum and stool have been of limited value13–15
in which some demonstrate significant correlation whereas
others do not. As an alternative to endoscopy and mucosal
biopsy and peripheral measures, we have used the proximal
portion of the Enterotest device16 17 to measure luminal
eosinophil-derived proteins and termed this section of the
Enterotest the oesophageal string test (EST). We hypothesised
that measurements of ESGPs and CLC/Gal10 directly in
oesophageal luminal secretions would reflect mucosal inflamma-
tion in EoE.
MATERIALS AND METHODS
Enterotest description
The Enterotest (HDC Corporation, Pilpitas, CA, USA), a min-
imally invasive string-based technology composed of a capsule
filled with approximately 90 cm of string, was originally
designed to detect gastric and small intestine pathogens, sample
bile and assess for gastro-oesophageal reflux disease (GORD)
(online supplementary figure S1A).17–19 In this study, one end
of the string (∼10 cm) was pulled from the capsule and wound
around the index finger (online supplementary figure S1B–D).
The capsule was swallowed, the proximal string taped to the
cheek (online supplementary figure S1E) and the remaining
string in the capsule deployed to end in the duodenal lumen,
where the capsule was dislodged.
We sampled luminal secretions from the proximal part of the
Enterotest string and termed this the EST. Locations of oesopha-
geal and gastric segments of the Enterotest were determined
using pH indicator sticks (online supplementary figure S1F) sup-
plied with tests, and if subjects were on antiacid medications, by
measuring the length to the lower oesophageal sphincter at the
time of endoscopy.
In vitro analysis of ESGPs and CLC/Gal-10 using the EST
See online supplementary methods.
Subject selection and Enterotest nylon string administration
Subjects between the ages of 7 and 20 years who were undergo-
ing an endoscopy with biopsy at either the Children’s Hospital
Colorado, Aurora, Colorado, USA or Ann and Robert H Lurie
Children’s Hospital of Chicago, Chicago, Illinois, USA to deter-
mine the causes of abdominal pain, vomiting, growth failure,
dysphagia or histological efficacy of EoE treatment were
enrolled in this study. Exclusion criteria included a history of
oesophageal stenosis (stricture or narrowing), gelatin allergy or
other causes that put subjects at increased risk (bleeding diath-
eses, connective tissue diseases) of endoscopic complications.
Histories were taken to record symptoms, allergic history, family
history and medications. Review of endoscopic and pathology
records were performed to assure diagnostic accuracy and deter-
mine clinical features.
Subject diagnoses were assigned according to the following cri-
teria based on published consensus recommendations:1 2 (1)
EoE-active: children with symptoms of oesophageal dysfunction
and oesophageal eosinophilia >15 eosinophils/HPF, in whom
other causes of symptoms and oesophageal eosinophilia were
ruled out; (2) EoE-remission: children with EoE as defined above
who had undergone at least 8 weeks of treatment (topical steroids
or dietary elimination) and who, at the time of their endoscopy,
were asymptomatic; (3) GORD: children with symptoms of vomit-
ing or heartburn who had responded to proton pump inhibitor
treatment and/or had an abnormal pH impedance monitor of the
distal oesophagus. Subjects were on proton pump treatment at the
time of the endoscopy; and (4) Normal: children with symptoms
that lead to endoscopic testing who were found to have histologi-
cally normal oesophageal, gastric and duodenal mucosae.
The night before endoscopic procedures, subjects swallowed
the Enterotest (online supplementary figure S1). Subjects could
drink liquids until 3 h before their endoscopic procedure. If
families or subjects desired, the subject was admitted to the
Research Center (Clinical and Translational Research Center) at
the Children’s Hospital Colorado or Ann and Robert H Lurie
Children’s Hospital of Chicago the night before the procedure.
The day after swallowing the Enterotests, subjects had upper
endoscopy performed. After anaesthesia was administered, the
Enterotest was removed, adherent secretions were eluted from
the proximal oesophageal section of the Enterotest and the
sample was immediately frozen for later batch analysis of the
ESGPs and CLC/Gal-10. The oesophageal string location was
determined as noted below (online supplementary figure S1F).
Mucosal pinch biopsies were then taken from oesophageal
mucosal surfaces and immediately snap frozen for eosinophil-
derived protein extraction and measurement. Diagnostic biop-
sies were placed in neutral buffered formalin for processing and
routine H&E (eosinophil enumeration) and immunohistochem-
ical (EPX Staining Index) staining.
This study was approved by the Colorado Multi-institutional
IRB (COMIRB) and IRBs of the University of Illinois at
Chicago and the Children’s Memorial Hospital.
Processing EST samples and biopsies for ESGPs and CLC/-10
biomarker assays
See online supplementary methods.
Quantitative measurement of ESGP and CLC/Gal-10
biomarkers
ESGP and CLC/Gal-10 levels present in EST samples and biopsy
extracts were determined using commercial (EDN, ECP; MBL
International, Woburn, MA, USA) or inhouse developed
(MBP1, CLC/Gal-10, EPX) ELISAs. Assays for EDN and ECP
were performed according to the manufacturer’s instructions.
Double-antibody sandwich ELISAs for MBP1 and CLC/Gal-10
were developed and standardised at the Ackerman laboratory
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(Chicago, IL, USA) and for EPX at the Lee laboratory
(Scottsdale, AZ, USA). MBP1 and CLC/Gal-10 ELISAs used
standard curves generated using the purified eosinophil-derived
protein, prepared as previously described.7 20–22 For MBP1,
mouse monoclonal antibodies were used for both capture and
detection (mouse anti-human MBP1-clones, J14-8A2 and
J13-6B6, respectively, kindly provided by Dr Hirohito Kita,
Mayo Clinic, Rochester, Minnesota, USA), the detection anti-
body being biotinylated and detected using streptavidin-
conjugated horseradish peroxidase (ExtraAvidin Peroxidase,
E2886; Sigma-Aldrich, St. Louis, Missouri, USA) and FAST
OPD Tablet substrate (P9187; Sigma-Aldrich). CLC/Gal-10
ELISAs used a mouse monoclonal capture antibody
(Anti-human Gal-10/CLC, Cell Sciences, Canton,
Massachusetts, USA), whereas the detection antibody was a
CLC/Gal-10 affinity purified rabbit polyclonal antibody pre-
pared as previously described.7 Detection antibodies for the
MBP1 and CLC/Gal-10 ELISAs were biotinylated using a
Biotin-XX Microscale Protein Labelling Kit (B30010;
Molecular Probes, Invitrogen, Eugene, Oregon, USA) according
to the manufacturer’s instructions. MBP1 and CLC/Gal-10
ELISA assays detected these eosinophil-derived proteins in the
ranges of 11.8–750 and 0.125–16 ng/ml, respectively, with
recoveries of 80%–100% and 100%–120%, signal to noise
ratios >5 and coefficient of variation (CV) of 15%.
Specific parameters and detailed protocol and methods asso-
ciated with the EPX-based ELISA in mice have been recently
described.23 EPX ELISA detected EPX in the range of 8–
1024 ng/ml, with recovery of 90%, signal to noise ratios >15
and an assay CVof 13%.
Histological analysis
Eosinophils were enumerated in formalin-fixed, H&E stained
tissue sections as previously described (KC, SS, JM, Denver;
HM, Chicago).24 Eosinophils were defined as having at least
one nuclear lobe identified in association with intracellular eosin
stained granules. Only epithelial eosinophils were enumerated
(surface area 0.26 mm2). Results were reported as peak (in one
mucosal sample from most densely populated section) and mean
eosinophils/HPF (from 5 HPFs counted). Analytical variability
of histological assessment was <5% and discrepancies between
investigators were resolved.
EPX immunohistochemistry and EPX scoring
Immunohistochemistry for EPX and determination of the EPX
Staining Index score for proximal and distal oesophageal biop-
sies were performed in formalin-fixed, paraffin-embedded tissue
sections as previously described.6
Statistical analysis
SAS V.1 9.2 was used for statistical analysis. Biomarker levels
were compared across groups using ANOVA. Since these
outcome variables were not normally distributed, logarithmic
transformation to the natural base was applied to the data,
where the value of 0 in biomarker level was coded as 10−6.
Spearman correlation coefficient (r) was used to assess the corre-
lations between biomarkers. Fisher’s z transformation was
applied when testing statistical significance of r. C-statistics (ie,
the area under receiver operating characteristic (ROC) curve)
were used to quantify the discriminating ability of a biomarker.
C value>0.7 was considered acceptable discrimination. ROC
was estimated from the logistic regression model with the level
of biomarkers being a continuous predictor.
RESULTS
Eosinophil-derived proteins bind to Enterotest nylon strings
in vitro
As determined by western blot analyses, Enterotest strings
detected a concentration dependent increase in MBP1 protein
from eosinophil lysates (online supplementary figure S2); EPX
and MBP1 were detected on Enterotest nylon strings as early as
1 h after incubation with lysates (online supplementary figure
S3). Strings were also able to detect EPX and MBP1 from IL-5
activated intact eosinophils (online supplementary figure S4) as
early as 1 h following incubations. Strings were also able to
capture another eosinophil-derived protein, EDN, from acti-
vated eosinophils (1×106) (online supplementary figure S5).
Together, these in vitro results supported the feasibility of using
Enterotest nylon strings in situ to capture eosinophil-derived
proteins.
Subject characterisation and tolerance of procedure
Forty-one subjects were recruited; no significant differences in
recruitment were identified between the two sites. Clinical char-
acteristics of these subjects are summarised in online supplemen-
tary table S1. No complications or endoscopic mucosal findings
were identified that were related to the performance of
Enterotests and a gagging sensation during swallowing the
capsule was the only problem reported.
Mucosal biopsy concentrations of ESGPs and CLC/Gal-10
differentiate subjects with active EoE from those with
treated EoE, GORD and normal subjects without
inflammation
Eosinophil enumeration has been the ‘gold standard’ biomarker
used for assessing mucosal inflammation. Thus, we first com-
pared the number of mucosal eosinophils (enumeration and
EPX Staining Index) with quantitative measurements of
eosinophil-derived proteins in biopsy extracts. Consistent
with previous studies, both eosinophil numbers and EPX
Staining Indices were significantly greater in subjects with
active EoE compared with EoE in remission, GORD and
normal controls (table 1). Eosinophil-derived protein concentra-
tions (figure 1; (A1) MBP1, (A2) EDN, (A3) ECP, (A4) EPX and
(A5) CLC/Gal-10) in oesophageal biopsy extracts were signifi-
cantly increased in subjects with active EoE compared with
treated EoE (MBP1, p<0.0001; EDN, p<0.0001; ECP,
p<0.001; EPX, p<0.05; CLC/Gal-10, p<0.001; active vs
treated), GORD (MBP1, p<0.001; EDN, p<0.0001; ECP,
p<0.001; EPX, p<0.05; active vs GORD) and to those with
normal mucosa (MBP1, p<0.0001; EDN, p<0.0001; ECP,
p<0.0001; EPX, p<0.001; CLC/Gal-10, p<0.0001 active
vs normal).
Next we wanted to determine whether mucosal biopsy con-
centrations of eosinophil-derived proteins correlated with trad-
itional and newer measurements of eosinophil burden. All
eosinophil-derived proteins tested correlated significantly with
peak eosinophil counts, mean eosinophil counts and EPX
Staining Indices measured in the above subject groups
(p<0.0001 for all eosinophil proteins vs peak eosinophil, mean
eosinophil and EPX Staining Index) (table 2A).
Together, these results determined that mucosal biopsy con-
centrations of eosinophil-derived proteins, similar to eosinophil
enumeration, serve as reliable measures of mucosal eosinophil
burden. In addition, measurements of biopsy extracts were sig-
nificantly different between disease states suggesting they were
reflective of disease activity.
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EST detection of ESGPs and CLC/Gal-10 differentiates
subjects with active EoE from those with treated EoE, GORD
and normal subjects without inflammation
To determine whether we could capture evidence of mucosal
inflammation by using an intraluminal device, we next measured
levels of luminal oesophageal eosinophil-derived proteins with
ESTs in subjects with active EoE, treated EoE, GORD and
normal oesophagus. Eosinophil-derived proteins (figure 1; (B1)
MBP1, (B2) EDN, (B3) ECP, (B4) EPX and (B5) CLC/Gal-10)
were significantly increased in EST samples obtained from sub-
jects with active EoE compared with those with treated EoE
(MBP1, p<0.001; EPX, p<0.01; CLC/Gal-10, p<0.0001;
active vs treated), GORD (MBP1, p<0.0001; EDN, p<0.0001;
CLC/Gal-10, p<0.01; active vs GORD) as well as subjects with
no histopathological evidence of oesophageal inflammation
(MBP1, p<0.0001; EDN, p<0.0001; ECP, p<0.01; CLC/
Gal-10 p<0.0001; active vs normal).
Luminal measurements of eosinophil-derived proteins
correlate with tissue measurements of mucosal eosinophilic
inflammation
To determine whether luminal concentrations of eosinophil-
derived proteins were reflective of tissue measurements of
eosinophil burdens, we performed correlational analyses of
eosinophil-derived protein concentrations obtained with ESTs
with three measures of eosinophilic inflammation present in the
tissue: (1) traditional gold standard measurement1 2—eosinophil
counts/HPF (peak and mean), (2) newer measurement6—EPX
Staining Index and (3) newest measurement (this study)—
eosinophil-derived protein levels in mucosal biopsy extracts
determined by ELISA. Concentrations of MBP1, EDN, EPX
and CLC/Gal-10 measured in EST samples obtained from all
subjects correlated significantly with eosinophil counts (figure 2;
A, peak eosinophils; B, mean eosinophils) and EPX indices
(table 2B). In addition, ESTassessments of all eosinophil-derived
proteins correlated significantly with measures of the same bio-
markers measured in extracts of matched mucosal biopsies
(MBP1, p<0.001; EDN, p<0.0001; ECP, p<0.001; EPX,
p<0.05 and CLC/Gal-10, p<0.0001) (figure 3). Together, these
results demonstrated that capture of luminal eosinophil-derived
biomarkers by ESTs provides an accurate reflection of oesopha-
geal mucosal eosinophilic inflammation.
ESTs can detect eosinophilic inflammation without evidence
of superficial inflammation
We next determined whether evidence of superficial mucosal
inflammation was necessary to detect luminal inflammation with
the EST. Of the 14 active EoE subjects, white exudates, micro-
abscess or superficial layering were seen in all but four subjects
despite each having detectable eosinophil-derived protein levels
in either their biopsy or EST samples. Except for one condition,
ECP versus microabscess (table 3, values in bold), no significant
correlations were identified between gross or histological mea-
surements of oesophageal mucosal inflammation with respect to
Table 1 Summary of histological and gross features of mucosal eosinophilia
EoE-active
(untreated), n=14
EoE-remission
(treated), n=8
GORD,
n=4
Normal oesophagus,
n=15
p Values untreated EoE versus
treated, GORD, normal
Eosinophil peak count (±SEM)
Proximal 30.1±6.0 0.4±0.3 0.3±0.2 0 p<0.001
Distal 45.4±8.9 0 0.8±0.4 0 p<0.001
Eosinophil average of five random fields (±SEM)
Proximal 17.4±3.9 0.1±0.1 0.3±0.2 0 p<0.001
Distal 28.9±6.0 0 0.3±0.2 0 p<0.001
EPX Staining Index*
Proximal 34.2±5.3 4.4±2.3 0 2.8±2.8 p<0.001
Distal 41.1±1.9 6.5±3.5 11.3±6.0 5.9±3.3 p<0.001
Endoscopic evidence of exudate (% of total
patients)
6 (43%) 2 (25%) 1 (25%) 0 p<0.001
Microabscess† (% of total patients) 11 (79%) 0 0 0 p<0.001
Superficial layering‡ (% of total patients) 9 (64%) 0 0 0 p<0.001
*Panels show representative images of immunohistochemical staining for EPX (red reaction product) in tissue sections from subjects with normal oesophagus, untreated EoE, treated
EoE in remission and GORD that were used to generate the EPX Staining Index in this study.
†Microabscess: four or more eosinophils adjacent to each other in the superficial epithelia.
‡Superficial layering: eosinophils within the luminal surface of the oesophageal epithelia.
EoE, eosinophilic oesophagitis; EPX, eosinophil peroxidase; GORD, gastro-oesophageal reflux disease.
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eosinophil-derived protein concentrations measured in mucosal
biopsies.
No significant correlations were identified between gross mea-
surements (white exudate) of oesophageal mucosal inflammation
with respect to eosinophil-derived protein concentrations mea-
sured from biopsy or EST samples (table 3). Except for two con-
ditions, MBP1 versus superficial layering and microabscess
(table 3, values in bold), no significant correlations were
detected when comparing histological evidence of superficial
epithelial inflammation (eosinophil microabscess and superficial
layering) with eosinophil-derived protein concentrations mea-
sured from ESTs. These results suggest that ESTs can capture
eosinophilic inflammation even if there is no evidence of super-
ficial mucosal inflammation.
EST-based assessment of eosinophil-derived proteins
represents a sensitive and specific test for oesophageal
eosinophil inflammation
We next sought to determine whether assessments of subjects
using mucosal biopsies and EST-based measurements of eosino-
phil specific proteins achieved diagnostic/therapeutic thresholds
that would permit their use to diagnose and monitor children
with EoE. ROC curves for eosinophil-derived protein concen-
trations of MBP1 and CLC measured in mucosal biopsies and
Figure 1 Eosinophil-derived protein levels in oesophageal biopsy and oesophageal string test (EST) samples. Oesophageal mucosal biopsies
concentrations of (A1) major basic protein-1 (MBP1), (A2) eosinophil-derived neurotoxin (EDN), (A3) eosinophil cationic protein (ECP), (A4)
eosinophil peroxidase (EPX) and (A5) Charcot–Leyden crystal protein/galectin-10 (CLC/Gal-10). Eosinophil secondary granule proteins and CLC/Gal-10
as measured by ELISA are shown in samples from subject groups (eosinophilic oesophagitis (EoE) active—black bars, EoE treated—light gray bars,
gastro-oesophageal reflux disease (GORD)—black bars, normal—white bars). Results are reported as ng of eosinophil protein per mg of total
protein in the biopsy extract. EST concentrations of (B1) MBP1, (B2) EDN, (B3) ECP (B4) EPX and (B5) CLC/Gal-10 from the same subject groups are
reported as ng of eosinophil protein per ml of EST supernatant. Biomarker levels were compared across groups using ANOVA. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001, NS, not significant.
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ESTs indicated a high predictive power with C=1.00 and
C=0.99 for mucosal biopsy sampling, and C=0.97 and C=0.97
for EST sampling, respectively (figure 4A). Significant predictive
values were also true for each of the other eosinophil-derived
proteins (figure 4B and online supplementary figure S6).
DISCUSSION
EoE is a chronic disease characterised histologically by epithelial
eosinophilia.1 2 To date, oesophageal eosinophilia can only be
fully assessed by procuring mucosal biopsies during endoscopic
procedures. While endoscopy with biopsy is a safe, efficacious
and commonly performed procedure, it is also costly, time con-
suming and carries potential complications. In an effort to
determine a less expensive, quicker and safer alternative to
endoscopic biopsy, we wondered whether mucosal eosinophilia
associated with EoE could be assessed in a less invasive manner
using an FDA-approved device, the Enterotest.16–18 We
hypothesised that detection of eosinophil-derived proteins in
the oesophageal lumen would be reflective of oesophageal
mucosal microenvironments. We used the proximal portion of
the Enterotest and termed this the EST. Results from these
studies demonstrate that: (1) ESTs captured luminal eosinophil-
derived proteins, (2) luminal eosinophil-derived protein concen-
trations correlated significantly with those present in oesopha-
geal mucosal biopsies and (3) luminal measures of inflammation
correlated with disease activity. Taken together, these results
demonstrate that measurements of luminal eosinophil-derived
proteins reflect mucosal inflammation in EoE.
Past difficulties in assessing oesophageal inflammation have
been characterised primarily by the inability to directly access
inflamed mucosal surfaces and the limited number of biomarker
(s) to assess disease activity. Attempts to measure biomarkers
from peripheral sites such as the blood or stool may or may not
be reflective of the oesophageal mucosal microenvironment, and
EoE studies to date have lacked sufficient sensitivity and specifi-
city to be clinically useful.13–15 Our study showed for the first
time that tissue concentrations of eosinophil-derived proteins
correlated with eosinophil number and likewise with disease
states. This novel finding provided us with another metric to
evaluate luminal measurements of eosinophil-derived proteins
captured by the EST.
Other measures of oesophageal function such as ultrasound,
endoflip, stationary and mobile motility monitoring and pH/
impedance monitoring are invaluable to document anatomy and
real-time oesophageal function, but they cannot analyse bio-
chemical features of oesophageal inflammation.25–27 Therefore,
we first tested the ability of the Enterotest to capture eosinophil
proteins from the oesophageal lumen. Consistent with previous
studies that used the Enterotest to geographically target different
sections of the gastrointestinal tract,16–19 we used the proximal
end of Enterotest to directly measure oesophageal inflammation
in children with EoE. Our results demonstrate that oesophageal
portions of the Enterotests or the EST detected luminal concen-
trations of eosinophil-derived proteins which correlated signifi-
cantly with the gold standard eosinophil enumeration (peak and
mean), the recently defined methodology, EPX Staining Index
and the herein described measurements of eosinophil-derived
proteins in biopsy extracts. The high degree of correlation of
eosinophil-derived proteins from EST samples with these
metrics provides very strong support for the use of the EST to
biochemically interrogate the oesophageal mucosa.
Our findings document the use of the EST to capture
eosinophil-derived proteins and its potential use as a device to
assist in monitoring therapeutic efficacy in patients with EoE. In
this regard, therapeutic efficacy could be monitored on a more
regular basis following changes in treatments or during exacerba-
tions of disease. However, the small number of GORD patients
studied to date, and the lack of commercially available standar-
dised ELISAS for a number of eosnophil biomarker, currently
obviate use of the EST as a diagnostic device for EOE pending
further studies.
Cellular and molecular profiles of secretions liberated from
mucosal surfaces of the intestinal, bronchial and rhinopulmon-
ary tracts provide robust and reproducible findings indicative of
disease activity in other diseases.28–30 In this regard, our study
as well as studies of patients with eosinophil-related diseases
Table 2 Correlations of eosinophil-derived protein concentrations from biopsy extracts and ESTs with histological measures of mucosal
eosinophilia
Peak eosinophils* Mean eosinophils* EPX Staining Index*
A. Biopsies r Value† p Value r Value† p Value r Value† p Value
MBP1 0.72559 <0.0001 0.72003 <0.0001 0.72052 <0.0001
EDN 0.78673 <0.0001 0.79306 <0.0001 0.75952 <0.0001
ECP 0.70621 <0.0001 0.70804 <0.0001 0.66968 <0.0001
EPX 0.61117 <0.0001 0.61596 <0.0001 0.60103 <0.0001
CLC/Gal-10 0.66360 <0.0001 0.66329 <0.0001 0.65902 <0.0001
EPX Staining Index*
B. ESTs r Value† p Value
MBP1 0.72170 <0.0001
EDN 0.47688 <0.002
ECP 0.20519 NS
EPX 0.54145 <0.0002
CLC/Gal-10 0.72735 <0.0001
*n=41 subjects for peak and mean eosinophil numbers and EPX index.
†Spearman’s rank correlation coefficient (r) for values from n=41 subjects.
CLC/Gal-10, Charcot–Leyden crystal protein/galectin-10; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EPX, eosinophil peroxidase; EST, oesophageal string test;
MBP1, major basic protein-1.
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such as asthma and allergic conjunctivitis revealed that eosino-
phils and their products are deposited generously within
affected mucosal surfaces and these can be captured in fluids
obtained from the lung, tears and now the oesophagus.31–36
Eosinophilic inflammation of the oesophageal mucosa may or
may not contain evidence of superficial eosinophilia as charac-
terised by endoscopic findings of white exudates, histological
patterns of microabscess formation and/or superficial
layering.3 5 6 37 38 Our results are highly suggestive that
eosinophil-derived proteins can be captured regardless of
whether gross or histological evidence of surface eosinophilia is
present, but further studies will need to be completed to valid-
ate this finding.
Eosinophil-derived proteins are biologically potent molecules
that carry significant functional activities relevant to the
mechanisms of pathogenesis in EoE. In animal models, MBP
Figure 2 Correlation of eosinophil-derived proteins in oesophageal string test samples with eosinophil counts in oesophageal mucosal biopsy
samples. Spearman analyses correlating oesophageal string test sample eosinophil-derived protein levels with peak (panel A, 1–5) and mean (panel
B, 1–5) eosinophil counts were performed. Spearman rank correlation coefficients (r) and associated p values are shown. EoE-no Rx (untreated—
active disease) (solid circles), EoE-Rx (treated—in remission) (open circles), GORD (open triangles) and normal oesophagus (open squares). CLC/
Gal-10, Charcot–Leyden crystal protein/galectin-10; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EoE, eosinophilic
oesophagitis; EPX, eosinophil peroxidase; GORD, gastro-oesophageal reflux disease; MBP1, major basic protein-1.
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has been shown to contribute to increased epithelial permeabil-
ity, smooth muscle contraction and liberation of molecules
related to tissue remodelling and fibrosis.11 12 39 40 These func-
tional properties bear particular relevance to patients with EoE.
Pathogenetic mechanisms related to EoE include alterations in
barrier function with dysregulated filaggrin expression,41 altered
oesophageal motility and oesophageal stricture formation/long
segment narrowing.26 27 Thus, ongoing identification and meas-
urement of eosinophil-derived proteins may provide additional
insights into pathogenetic mechanistic pathways.
In this study, ESTs captured eosinophil-derived proteins suc-
cessfully, but a few technical and biological issues remain to be
addressed. Whereas this study focused on measurements of
eosinophil-derived proteins as a biomarker of EoE, future
studies will need to identify novel intraluminal biomarkers that
will allow for the differentiation of EoE from other forms of
oesophagitis. Identification and validation of these biomarkers
will then offer increased diagnostic capacity of the device, espe-
cially in the assessment of patients with dysphagia and other
symptoms referable to the oesophagus. To maximise the ability
of ESTs to harvest measureable levels of eosinophil-derived pro-
teins from oesophageal secretions, this study was performed
leaving ESTs in the oesophagus overnight. The eventual use of
ESTs will be best suited to an office setting, and ongoing studies
are testing shorter incubation times. Contamination from swal-
lowed oropharyngeal or refluxed gastric secretions may alter
oesophageal measurements, but our data (not shown) related to
gastric contamination suggest low inconsequential eosinophil-
derived protein levels in the stomach. Minimally detectable
levels of eosinophil-derived proteins in normal patients could
have been from undetected oesophageal inflammation in swal-
lowed nasal/oral secretions; these levels did not reach those
detected in active EoE patients. The primary sources of proteins
measured here are eosinophils, but basophils, mast cells, neutro-
phils and T lymphocytes also express or sequester low levels of
some of these proteins.42–49 These sources may also help to
explain the non-zero values of ESGPs in control and treated
subjects.
Figure 3 Correlation of eosinophil-derived protein concentrations in
luminal oesophageal string test (EST) samples with eosinophil-derived
proteins in oesophageal mucosal biopsy samples. (A) major basic
protein-1 (MBP1), (B) eosinophil-derived neurotoxin (EDN), (C) eosinophil
cationic protein (ECP), (D) eosinophil peroxidase (EPX) and (E) Charcot–
Leyden crystal protein/galectin-10 (CLC/Gal-10) concentrations in EST and
mucosal biopsy extracts were correlated using Spearman analyses (rank
correlation coefficients (r) and associated p values). Eosinophilic
oesophagitis (EoE)-no Rx (untreated—active disease) (solid circles),
EoE-Rx (treated—in remission) (open circles), gastro-oesophageal reflux
disease (GORD) (open triangles) and normal oesophagus (open squares).
Table 3 ESTs can detect eosinophilic inflammation without
evidence of superficial inflammation
Sample
source
White exudate
(8 without vs
6 with)
p value*
Superficial layering
(9 without vs
5 with)
p value*
Microabscess
(9 without vs
5 with)
p value*
MBP1 Biopsies 0.6354 0.4457 0.0817
ESTs 0.4921 0.0325 0.0430
EDN Biopsies 0.0681 0.2850 0.2137
ESTs 0.3718 0.2475 0.5314
ECP Biopsies 0.1573 0.1342 0.0384
ESTs 0.0507 0.7435 0.8338
EPX Biopsies 0.1445 0.5722 0.7302
ESTs 0.5830 0.2279 0.3776
CLC/
Gal-10
Biopsies 0.7754 0.6341 0.4833
ESTs 0.6070 0.2490 0.2881
Active EoE subjects (14) with or without evidence of superficial mucosal
inflammation (noted in parentheses in table) were compared with each other for
each of the eosinophil-derived proteins from each sample source (biopsy or EST).
*From two sample t tests comparing subjects with versus those without a particular
endoscopic/histological condition. Statistically significant values (p<0.05) are in
bold.
CLC/Gal-10, Charcot–Leyden crystal protein/galectin-10; ECP, eosinophil cationic
protein; EDN, eosinophil-derived neurotoxin; EoE, eosinophilic oesophagitis; EPX,
eosinophil peroxidase; EST, oesophageal string test; MBP1, major basic protein-1.
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In summary, we have demonstrated the use of a minimally
invasive test, the EST, to document mucosal inflammation in
children with EoE. Although we do not suggest that the EST
will replace endoscopy and biopsy as a critical tool for analyses
of EoE, it certainly has the potential to significantly improve the
evaluation and treatment of patients with EoE who may require
repeated assessments of their oesophageal mucosae. In addition,
as future biomarkers are identified and validated for EoE, ESTs
may be able to differentiate patient phenotypes that are more
predisposed to complications or responsive to various
treatments.
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